Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma With Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.

Conclusion These results demonstrate high and durable ORR and CR rates in patients with relapsed/refractory MCL. Zanubrutinib was generally well-tolerated; grade ≥3 BTK inhibitor-associated toxicities (hemorrhage, rash, hypertension, diarrhea, atrial fibrillation) were uncommon.
PMID: 32461234 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - May 26, 2020 Category: Cancer & Oncology Authors: Song Y, Zhou KS, Zou D, Zhou J, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Guo H, Zhou L, Elstrom R, Huang J, Novotny W, Wei R, Zhu J Tags: Clin Cancer Res Source Type: research